Risk factors of stroke and −717A&gt;G (rs2794521) CRP gene polymorphism among stroke patients in West Pomerania province of Poland by Kotlęga, Dariusz et al.
Original research article
Risk factors of stroke and S717A > G (rs2794521) CRP gene
polymorphism among stroke patients in West Pomerania
province of Poland
Dariusz Kotlęga a,*, Monika Białecka b, Mateusz Kurzawski b, Marek Droździk b,
Sylwester Ciećwież c, Monika Gołąb-Janowska a, Przemysław Nowacki a
aDepartment of Neurology, Pomeranian Medical University, Szczecin, Poland
bDepartment of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland
cDepartment of Gynaecology and Urogynaecology, Pomeranian Medical University, Szczecin, Poland
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 8 ( 2 0 1 4 ) 3 0 – 3 4
a r t i c l e i n f o
Article history:
Received 12 August 2012
Accepted 23 December 2013






a b s t r a c t
Background and purpose: Some of the risk factors of ischaemic stroke inﬂuence the develop-
ment of atherosclerosis, which is a signiﬁcant cause of vascular incidents. An inﬂammatory
component plays a role in pathogenesis of both atherosclerosis and atrial ﬁbrillation, the
most important risk factor of embolic strokes. C-reactive protein (CRP) concentration in
blood reﬂects the inﬂammatory process. Concentration of this protein depends on the CRP
gene polymorphism. The aim of the study was to assess the relationship between selected
risk factors of stroke and variant of 717A > G (rs2794521) CRP gene polymorphism in
population of West Pomerania Province of Poland.
Materials and methods: There were 125 consecutive patients with ischaemic stroke analysed,
who met the inclusion and exclusion criteria. In all patients, 717A > G CRP gene polymor-
phism was genotyped and analysed in relation to selected stroke risk factors.
Results: Prevalence of type 2 diabetes was lower in patients with AA genotype of 717A > G
CRP gene polymorphism than in patients with other alleles ( p = 0.017). Subjects with GG
genotype had signiﬁcantly higher concentration of CRP comparing to AG genotype
( p = 0.023). No correlation was found between 717A > G CRP gene polymorphism and
the lipid proﬁle and other selected risk factors of stroke.
Conclusions: In patients with ischaemic stroke in West Pomerania Province, the GG genotype
of 717A > G CRP gene polymorphism is associated with signiﬁcantly higher CRP concen-
tration in relation to AG genotype. Patients with AA genotype may be characterised by lower
prevalence of type 2 diabetes.
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Stroke is the third cause of death and ﬁrst cause of permanent
disability, especially among people more than 60 years of age
[1]. Between 2004 and 2006, the incidence of ischaemic stroke
in European population amounted to 114.7 in men and 74.9 in
women, while in Polish population it reached 147.2 and 125.9
per 100 000, respectively [2]. In a study covering relatively
small population in Poland between 2005 and 2006, much
higher incidence of ischaemic stroke and intracerebral
haemorrhage was noted: 211/100 000 for men and 130/
100 000 for women (mean 167/100 000) [3].
Pathogenesis of particular types of ischaemic stroke is
associated with risk factors. Understanding of these factors
enables proper stroke prevention. Inﬂammatory factors play a
substantial role in the process that leads to atherosclerosis
development. It is reﬂected by increased level of C-reactive
protein (CRP) in patients with advanced atherosclerosis [4,5].
The blood CRP level is applicable in the assessment of risk and
prognosis in stroke patients. Nevertheless, blood level is liable
to be modiﬁed by environmental (inﬂammatory disorders,
statins) and genetic (gene polymorphism) factors.
CRP is produced as the response on inﬂammatory stimuli
largely under control of inﬂammatory cytokines including
interleukin-6 (Il-6) and tumour necrosis factor-a (TNF-a) [5,6].
Development of atherosclerotic lesions observed in carotid
arteries correlates with increased CRP [7]. C-reactive protein
level correlates with the increased risk of ischaemic stroke in
general population and asymptomatic stenosis of internal
carotid artery [8,9]. It was shown that inﬂammatory factors
take part in the atrial ﬁbrillation (AF) pathogenesis that is
associated with embolic strokes [10]. Positive correlation
between AF incidence and CRP level was found [5,11–14].
The expression of CRP is genetically conditioned. The CRP
gene is localised on chromosome 1 (1q21–1q23) and is
characterised by genetic variability. There has been about 30
CRP gene single nucleotide polymorphisms (SNP) described so
far [15]. The relationship between particular SNP allele (variants)
and diverse CRP expression was shown, but these results
indicate both increase and decrease of CRP [7,16–20]. Depending
on SNP variant of CRP gene, there have been revealed some
differences in death risk in stroke patients, risk of recurrent
stroke in patients with symptomatic internal carotid artery
stenosis, cardiogenic stroke, risk of intracranial atherosclerosis
and intima-media complex thickness (IMT) development
[15,21–24]. Results of studies investigating relationship between
CRP and 717A > G (rs2794521) CRP gene polymorphism are
contradictory [16,17,25–28]. Individuals carrying the 717A
allele had a 6.84-fold higher risk of developing coronary heart
disease when compared with those not carrying this allele [28].
The risk of myocardial infarct and ischaemic stroke is decreased
depending on 717A > G genotype [15,29]. In vitro studies
suggested that differences in transcriptional activity depending
on 717A > G CRP gene SNP – the G to A substitution at the site of
rs2794521 resulted in increased transcriptional activity of the
promoter of CRP gene [30].
As the examples given above, despite intensive studies in
the ﬁeld of CRP gene polymorphism role in the stroke
pathogenesis, obtained results are contradictory. It is also inregard to the association between 717A > G CRP gene SNP,
CRP level and incidence risk of vascular episodes. CRP is the
independent risk factor of stroke and additionally exert
indirectly an effect throughout the pathogenetic link with
atherosclerosis, AF and type 2 diabetes [31,32]. Investigation of
mutual interactions between CRP gene genotype and presence
of stroke risk factors may be thus helpful in a detection of
novel connections on immune-inﬂammatory basis.
2. Materials and methods
There were 125 consecutive subjects enrolled in the study, who
were hospitalized in the Neurology Clinic of the First
Independent Public Clinical Hospital of Pomeranian Medical
University (SPSK 1 PUM) in Szczecin between January 2008 and
June 2010, of age above 18, that were inhabitants of West
Pomerania Province. Main inclusion criterion was diagnosis of
ischaemic stroke on the ﬁrst day after the symptoms onset,
conﬁrmed by clinical examination and brain neuroimaging
tests (computed tomography or nuclear magnetic resonance)
[33]. Patients with both atherothrombotic and embolic stroke
were enrolled in the study.
Written consent to participate in the study was obtained
from a patient or caregiver. Local Bioethical Committee
approval was also obtained (resolution No. BN-001/118/07
KBP, Szczecin, 27th of November 2007).
We excluded patients with body temperature of more than
37.4 8C, clinical or biochemical features of infection, chronic
inﬂammatory disorders, cancers and those treated with any of
3-Hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors
(statins) within last year.
Presence of risk factors was established upon history and
medical records. Hypertension and diabetes were diagnosed
upon history and during hospitalisation. The body mass index
(BMI) was calculated by body mass in kilograms divided by
squared-height, in metres. Assessment of common, internal
carotid arteries and vertebral arteries was made with the use of
GE LOGIQ Book XP camera, linear head 7.5 MHz. Transcranial
measurement of systolic and diastolic pressure in middle
cerebral arteries was made with the use of Multi-Dop P System
ultrasonography, head 2 MHz (DWL Elektronische Systeme
GmbH). The complex of intima-media was described as the
distance between lines demarcating the artery lumen and
inner wall (intima) to media and adventitia. IMT was measured
on the distal wall of common carotid arteries in the distal part
[34,35].
Atherosclerotic plaques within carotid arteries were iden-
tiﬁed according to guidelines from Manheim consensus [36].
The stenosis grade of carotid arteries was considered for the
bifurcation of common carotid artery or extracranial part of
internal carotid artery.
Biochemical laboratory tests were made in the Central
Laboratory of SPSK 1 PUM. Blood CRP level was measured using
immunoturbimetric method enhanced by latex, with the
lowest detection level of 1 mg/L.
DNA was isolated from the venous blood that was collected
into EDTA anticoagulant tubes.
The 717A > G CRP gene SNP (rs2794521:C > T) was
detected in the promoter region of CRP gene with the use of





BMI (kg/m2) 27.7 (4.2) 27.1 (19.5–43.4)
SBP on admisssion (mm Hg) 160.3 (30.9) 158 (102–280)
DBP on admission (mm Hg) 92.4 (18.6) 90 (60–180)
Glycaemia on admission (mg/dL) 133.3 (56.9) 114 (50–382.9)
CRP (mg/L) 5.77 (7.93) 3.1 (0.5–69.6)
Total cholesterol (mg/dL) 224.8 (44.6) 219 (65–396)
HDL (mg/dL) 49.7 (12.2) 50 (25–88)
LDL (mg/dL) 146.4 (36.2) 141 (55–255)
Triglycerides (mg/dL) 154 (93.6) 135 (53–704)
SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic
blood pressure; CRP, C-reactive protein; HDL, high density lipopro-
teins; LDL, low density lipoproteins.
a Body mass index (BMI) was assessed in 86 subjects.
Table 2 – Risk factors of ischaemic stroke.
Variable n %
Hypertension 100 80
Coronary heart disease 43 34.7
Previous acute coronary syndrome 12 9.6
Type 2 diabetes 27 21.6
Present cigarette smoking 64 51.6
Previous stroke/transient ischaemic attack 10 8
Heart rhythm disturbances 24 19.2
Occlusion of carotid arteries 18 14.6
Stenosis of carotid arteries 50% 37 26.1
Atherosclerotic plaques in carotid arteries 95 77.3
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Fragment Length Polymorphism) with Bsh1236I enzyme, in the
Department of Experimantal and Clinical Pharmacology of
Pomeranian Medical University [28].
3. Statistical analysis
Investigated parameters were evaluated by the sample size,
arithmetic mean, median, standard deviation, minimum
and maximum value (continuous variables). CRP level,
because of the right-oblique distribution, was logarithmi-
cally transformed. Arithmetic means were compared be-
tween studied polymorphisms with the use of one-way
analysis of variance (ANOVA) and least signiﬁcant difference
(LSD) as post hoc test.
The frequency values of discrete variables, characterised by
counts and percentages were analysed in fourfold table;
Pearson x2 test was applied. Statistical signiﬁcance of all
analyses was set as p < 0.05.
4. Results
There were 79 (63%) men enrolled in the study; mean age of
subjects was 64.3 years (standard deviation [SD] = 11.2, range:Table 3 – Comparison of incidence of selected risk factors of st
Parameter AA genotype (n) 
Stenosis of carotid arteries 50% 16 
Hypertension 55 
Coronary heart disease 22 
Previous acute coronary syndrome 7 
Type 2 diabetes 9 
Previous stroke/transient ischaemic attack 4 
Heart rhythm disturbances 9 
Atherosclerotic plaques in carotid arteries 47 
NS, not signiﬁcant.
a Pearson x2 test.
b For comparison of: AA vs. AG + GG.39–89 years). Prehospital hypertension treatment was applied
in only 46% subjects. Previous diabetes treatment was used in
12%. The most frequent heart rhythm disturbances were
chronic (9.6%) and paroxysmal (7.2%) AF. Alcohol abuse was
revealed in 12%. In the period preceding hospitalisation, 20% of
patients had been receiving antiplatelets, and only 3% – oral
anticoagulants. During hospitalisation, antiplatelet treatment
was used in 98%, oral anticoagulants in 13%, alteplase in 5%.
Diabetic drugs were used in 18%. (Tables 1 and 2).
In the group of our patients, AA genotype of 717A > G CRP
gene polymorhism was the most common (n = 67, 53.6%), AG
genotype was present in 50 cases (40%) and GG genotype in 8
subjects (6.4%). The genotype distribution was consistent with
awaited, appointed upon Hardy–Weinberg rule [37].
CRP level was signiﬁcantly higher in GG genotype patients
when compared to AG genotype ( p = 0.23, LSD post hoc test).
Borderline correlation was observed between CRP level
measured on the ﬁrst day of hospitalisation and 717A > G
CRP gene SNP in all subjects ( p = 0.069, ANOVA test).
As presented in Table 3, there was an association between
type 2 diabetes and 717A > G CRP gene polymorphism
( p = 0.05). When AA genotype was compared to AG + GG
genotypes, the AA patients were characterised by signiﬁcantly
less frequent incidence of diabetes in relation to other patients
( p = 0.017). No relationship was noted between 717A > G CRP
gene polymorphism and either selected parameters men-
tioned in Table 3 or lipid proﬁle (total cholesterol, LDL, HDL,
triglycerides). No signiﬁcant relations were found between
717A > G CRP gene polymorphism, systolic and diastolic
blood pressures and in relation to left and right IMT.roke and genotype of the S717A > G CRP gene.
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The distribution of 717A > G CRP gene polymorphism in our
patients was as follows: AA (53.6%), AG (40%), and GG (6.4%). In a
study conducted in a group of healthy Korean men, the
distribution was different: AA – 2%, AG – 22%, GG – 76% [26].
This difference may result from race dissimilarities that are
observedininﬂammatorycytokines polymorphisms [38]. Onthe
other hand, the AA genotype may be a stroke risk factor. In
another study, a distribution consistent with our results was
found [25]. Further studies are necessary to answer the question
if 717A > G CRP gene polymorphism may bea stroke risk factor.
We were mainly interested in plausible association
between 717A > G CRP gene polymorphism and selected
stroke risk factors. In the ﬁrst step, the analysed genotype was
related to CRP level. It was found in the LSD post hoc test that
CRP was signiﬁcantly higher in GG genotype patients when
compared to AG ( p = 0.023), while in the ANOVA test there was
no statistical signiﬁcance, but only a tendency ( p = 0.069). Till
now, only in one study it was shown that stroke patients with
AG and GG genotype had higher CRP levels than AA genotype
patients [26]. In other studies, there was no relationship found
between any of the 717A > G CRP gene polymorphisms and
CRP level [16,17,25,27,28].
The effect of CRP and other inﬂammatory cytokines on the
risk of type 2 diabetes raises no doubts. The relationship
between inﬂammatory molecules' genetic variants e.g. ﬁbrino-
gen with certain disorders is not clear and fully known [31,32,39].
In the analysed group it was shown that AA genotype compared
to other patients was associated with less frequent incidence of
type 2 diabetes ( p = 0.017). There are no previous studies on the
association between 717A > G CRP gene polymorphism and
diabetes, but other CRP gene polymorphisms were investigated.
No relationship was found in relation to rs12093699 CRP gene
polymorphism, but signiﬁcant association was found in
rs3093059 (OR 7.01; 95% CI: 1.16–42.22; p = 0.03) and rs133552
CRP gene polymorphisms [31,40,41].
In our study, no relationship between 717A > G CRP gene
polymorphism and other, selected stroke risk factors was
found. Further search for such relationships seems to be
reasonable, especially in relation to risk factors connected
with inﬂammation, such as AF. In the genome-wide associa-
tion study (GWAS) the relationship between T allele of
rs2200733 polymorphism on 4q25 chromosome and cardioem-
bolic stroke, especially with the AF background was found [42].
Observations made in our study are useful in terms of further
studies and efﬁcacy improvement of prevention and treatment
of ischaemic stroke patients. We are aware of methodological
limitations related to the small sample size that additionally
were in the acute phase of stroke which is accompanied by the
complex immune and inﬂammatory processes.
6. Conclusions
1. In stroke patients recruited in the West Pomerania province
of Poland, the GG genotype of 717A > G CRP gene
polymorphism is associated with higher CRP level com-
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